GC
GALT icon

Guggenheim Capital’s Galectin Therapeutics GALT Stock Holding History

Guggenheim Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-10,390
Closed -$35K – 2795
2017
Q4 		$35K Sell
10,390
-1,298
-11% -$3.28K ﹤0.01% 2647
2017
Q3 		$25K Sell
11,688
-21
-0.2% -$42 ﹤0.01% 2732
2017
Q2 		$29K Hold
11,709
– – ﹤0.01% 2764
2017
Q1 		$27K Buy
11,709
+70
+0.6% +$106 ﹤0.01% 2758
2016
Q4 		$11K Hold
11,639
– – ﹤0.01% 2875
2016
Q3 		$13K Buy
+11,639
New +$20.7K ﹤0.01% 2857
2014
Q3 		– Sell
-11,406
Closed -$157K – 3035
2014
Q2 		$157K Buy
11,406
+883
+8% +$11K ﹤0.01% 2942
2014
Q1 		$161K Buy
+10,523
New +$150K ﹤0.01% 2938

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
EGI
EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return
BCA
Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return

Guggenheim Capital's GALT Position: Q1 2018 in Review

Guggenheim Capital sold out of Galectin Therapeutics (GALT) in Q1 2018, closing a stake of 10,390 shares — an estimated $35K sold.

Guggenheim Capital first reported a position in GALT in Q1 2014 and held it in 8 quarters. The position peaked at $161K in Q1 2014. 62 funds tracked by Wall St. Rank hold GALT as of Q1 2018.

  • Guggenheim Capital reported no remaining Galectin Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Guggenheim Capital sold 10,390 Galectin Therapeutics shares in Q1 2018, an estimated $35K.
  • Guggenheim Capital first reported a position in Galectin Therapeutics in Q1 2014 and held it in 8 quarters.
  • Guggenheim Capital's Galectin Therapeutics position peaked at $161K in Q1 2014.
  • 62 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2018.

Based on Guggenheim Capital's 13F filing for Q1 2018, filed 15 May 2018.